ZBP1 and metastatic malignant neoplasm: In summary, our sono‐controllable Janus hydrogel platform integrates strategies of ROS modulation, ZBP1 regulation, and oxygen supplementation, offering a groundbreaking therapeutic approach for treating metastatic cancer and bone defects with clinically promising dual‐targeted effects.